Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: Results of a French prospective multicenter study

Laboratory Investigation

Volumn 83, Issue 6, 2003, Pages 845-852

  Piaton, Eric ^a,k   Daniel, Laurent ^b   Verriele, Véronique ^c   Dalifard, Isabelle ^c   Zimmermann, Ute ^d   Renaudin, Karine ^e   Gobet, Françoise ^f   Caratero, Anne ^g   Desvaux, Dominique ^h   Pouille, Yves ⁱ   Seigneurin, Daniel ^j  

^a INSERM   (France)

^b TIMONE HOSPITAL   (France)

^c CENTRE PAUL PAPIN   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e HÔTEL DIEU   (France)

^f HÔPITAL CHARLES NICOLLE   (France)

^g CHU RANGUEIL   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ Ferring SAS   (France)

^j HÔPITAL MICHALLON   (France)

^k EDOUARD HERRIOT HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER TUMOR; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE IMMUNOCYTOCHEMISTRY ASSAY; FRANCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENT CANCER; TRANSURETHRAL RESECTION; TUMOR BIOPSY; URINE CYTOLOGY; UROTHELIUM;

EID: 12444265382     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000074893.70675.2E     Document Type: Article

References (30)

1. Bastacky S, Ibrahim S, Wilczinski SP, et al (1999). The accuracy of urinary cytology in daily practice. Cancer (Cancer Cytopathol) 87:118-128.
2. Bunting P, Fleshner N, Kapusta L, et al (2000). Detection of bladder cancer via non-invasive methods: A direct comparison between the NMP-22 and ImmunoCyt+ tests (Abstract). J Urol 163:134.
3. Cassel A, Rahat MA, Lahat N, et al (2001). Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: An unfulfilled promise. J Urol 166:841-844.
4. Clark KR and Higgs MJ (1990). Urinary infection following out-patient flexible cystoscopy. Brit J Urol 66:503-505.
5. Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the Bladder Consensus Conference Committee (1998). The World Health Organization/International Society of Urological Pathology Consensus Classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22:1435-1448.
6. Ferlay J, Bray F, and Pisani P (2000). GLOBOCAN cancer incidence, mortality and prevalence worldwide, version 1.0. Available at: http://www-dep.iarc.fr
7. Fradet Y, Lockhart C, and the ImmunoCyt+ trialists (1997). Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt+. Canad J Urol 4:400-405.
8. Giannopoulos A, Manousakas T, Gounari A, et al (2001). Comparative evaluation of the diagnostic performance of the BTA Stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumours. J Urol 166:470-475.
9. Gourlay W, Chan V, and Gilks CB (1995). Screening for urothelial malignancies by cytologic analysis and flow cytometry in a community urologic practice: A prospective study. Mod Pathol 8:394-397.
10. Halling KC, King W, Sokolova IA, et al (2000). A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164:1768-1775.
11. Hölmang S, Andius P, Hedelin H, et al (2001). Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 165:1124-1130.
12. Jordan A, Weingarten J, and Murphy WM (1987). Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 60:2766-2774.
13. Kausch I and Bohle A (2001). Bladder cancer II. Molecular aspects and diagnosis Eur Urol 58:498-506.
14. Konety BR and Getzenberg RH (2001). Urine based markers of urological malignancy. J Urol 165:600-611.
15. Koss LG (1995). Diagnostic cytology of the urinary tract with histopathologic and clinical correlations. Philadelphia: JB Lippincott.
16. Lodde M, Mian C, Wiener H, et al (1999). ImmunoCyt+: A new tool for the detection of transitional cell cancer of the urinary tract (Abstract). Poster presented at AUA and EAU Meetings. J Urol 161:574.
17. Lodde M, Mian C, Wiener H, et al (2001). Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt+: A preliminary report. Urology 58:362-366.
18. Lodde M, Mian C, Negri G, et al (2003). Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology 61:243-247.
19. Lotan Y and Roehrborn CG (2003). Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology 61:109-118.
20. Mian C, Pycha A, Wiener H, et al (1999). ImmunoCyt+: A new tool for detecting transitional cell cancer of the urinary tract. J Urol 161:1486-1489.
21. Murphy WM (1990). Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 21:886-896.
22. Olsson H and Zackrisson B (2001). ImmunoCyt+: A useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 35:280-282.
23. Ozen H and Hall MC (2000). Bladder cancer. Curr Opin Oncol 12:255-259.
24. Ponsky LE, Sharma S, Pandrangi L, et al (2001). Screening and monitoring for bladder cancer: Refining the use of NMP22. J Urol 166:75-78.
25. Ramakumar S, Bhuiyan J, Besse JA, et al (1999). Comparison of screening methods in the detection of bladder cancer. J Urol 161:388-394.
26. Saad A, Hanbury DC, McNicholas TA, et al (2001). The early detection and diagnosis of bladder cancer: A critical review of the options. Eur Urol 39:619-633.
27. Sanchez-Carbayo M, Urrutia M, Silva JM, et al (2001). Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 165:1462-1467.
28. Sarosdy MF, Hudson MA, Ellis WJ, et al (1997). Improved detection of recurrent bladder cancer using the Bard BTA test. Urology 50:349-353.
29. Sarosdy MF, Schellhammer P, Bokinsky G, et al (2002). Clinical evaluation of a multi-target fluorescence in situ hybridization assay for detection of bladder cancer. J Urol 168:1950-1954.
30. Vriesema JLJ, Atsma F, Kiemeny LALM, et al (2001). Diagnostic efficacy of the ImmunoCyt+ test to detect superficial bladder cancer recurrence. Urology 58:367-371.